CHLORPHENIRAMINE Drug Patent Profile
✉ Email this page to a colleague
When do Chlorpheniramine patents expire, and when can generic versions of Chlorpheniramine launch?
Chlorpheniramine is a drug marketed by Aurolife Pharma Llc, Bel Mar, Elkins Sinn, Watson Labs, Pharm Assoc, Avanthi Inc, Anabolic, Bell Pharma, Impax Labs, Ivax Sub Teva Pharms, Kv Pharm, Lederle, Newtron Pharms, Panray, Pharmavite, Pharmeral, Pioneer Pharms, Purepac Pharm, Pvt Form, Roxane, Sun Pharm Industries, Vitarine, and West Ward. and is included in thirty NDAs.
The generic ingredient in CHLORPHENIRAMINE is chlorpheniramine maleate. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the chlorpheniramine maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Chlorpheniramine
A generic version of CHLORPHENIRAMINE was approved as chlorpheniramine maleate by AVANTHI INC on May 13th, 2009.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CHLORPHENIRAMINE?
- What are the global sales for CHLORPHENIRAMINE?
- What is Average Wholesale Price for CHLORPHENIRAMINE?
Summary for CHLORPHENIRAMINE
| US Patents: | 0 |
| Applicants: | 23 |
| NDAs: | 30 |
| Drug Prices: | Drug price information for CHLORPHENIRAMINE |
| DailyMed Link: | CHLORPHENIRAMINE at DailyMed |



